ADVENTRX Pharmaceuticals and Pierre Fabre Medicament have entered into a multi-year agreement under which Pierre Fabre will produce the active ingredient in ANX-188 (purified poloxamer 188) for use in clinical trials.
"We are delighted that the two companies have signed this multi-year agreement," said Frederic Duchesne, president of the Pharmaceuticals Division of Pierre Fabre. "Such a partnership is very exciting for the whole Pierre Fabre team. We are convinced of the high potential of ANX 188, and our dedicated Supercritical Fluids unit, chosen by ADVENTRX to manufacture the ANX-188 active ingredient, will have the opportunity to put its cutting-edge expertise at the service of a unique manufacturing process."
"We continue to make progress in the development of ANX-188 and the Phase III study we plan to begin later this year. Pierre Fabre is an experienced manufacturer with an impeccable reputation for quality that manufactures a number of products for commercial sale," said Brian M. Culley, chief executive officer of ADVENTRX. "Working with Pierre Fabre will enhance our proprietary position in the unique manufacturing process we have developed for ANX-188 and the long-term commercial value of ANX-188."